NCT03302884View on ClinicalTrials.gov

Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma

NAUnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Ovarian Carcinoma
Interventions
OTHER

biological sampling

Tumor and blood samples

Trial Locations (3)

34298

RECRUITING

Institut Du Cancer de Montpellier, Montpellier

59000

RECRUITING

Centre Oscar Lambret, Lille

63011

RECRUITING

Centre Jean Perrin, Clermont-Ferrand

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Institut Paoli-Calmettes

OTHER